Panel · Use case · Quality

Post-Marketing Requirement Review.

LiveBenefit-Risk Panel

A post-marketing requirement has delivered its first results. Do they change the balance, and what do they mean for the risk-minimisation measures in place?

DecisionWhether the first results change the balance and the measures

FunctionsQuality, safety, HEOR, clinical operations

ReaderSafety and quality leads

Not askedA study redesign

DepthStandard, four seats

Post-Marketing Requirement Review is a ready-made use case for Quality. It ships under the Benefit-Risk Panel template.

For quality leads. You get the effects table, each seat's conclusion, the weighing matrix, the uncertainties and the risk-minimisation measures. Claims are cited or marked as gaps.

Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.

The decision

A post-marketing requirement has delivered its first results. Do they change the balance, and what do they mean for the risk-minimization measures in place?

Who weighs

A post-marketing requirement is a study the sponsor must do after approval. First results may be interim, and the seats read them with the measures already in place.

Seat	What it weighs	What it works from
Director Quality Assurance	Whether the data are reliable and the measures are working as designed.	Quality records and measure effectiveness data.
Head of Pharmacovigilance	What the results say about the risks and whether the label needs to change.^{2European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module XVI – Risk minimisation measures.}	GVP Module XVI.
HEOR Evidence Lead	What the results mean for value and for payers who rely on the evidence.	Assessment methods.
Clinical Operations Director	How complete the study is and what interim data can and cannot show.	Study status and enrollment.

What the assessment does

Interim is not final. The effects table marks whether each result is interim or final and the uncertainty that follows from that.^{1U.S. Food and Drug Administration. Postmarketing Requirements and Commitments.}

Do the measures work? The risk minimization table states for each measure whether the data show that it is working, and what would show that it is not.^{2European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module XVI – Risk minimisation measures.}

What would change the balance. The report names the result that would move the conclusion and the date it is expected.

Recommended length

Standard

Four functions read the effects differently. Standard depth gives each a seat and shows the weighing matrix and the risk minimization table in about four pages.

You can pick another length on the form. The other two stay available.

Assumptions the assessment makes

The assessment states what it assumes about the evidence and the setting, and says what each gap limits. Examples for this decision:

The study population represents real use.
The interim data are not driven by an early signal that will fade.
The measures in place were implemented as designed.

Standards, guidance and sources

Frame

FDA, postmarketing requirements and commitments.^{1U.S. Food and Drug Administration. Postmarketing Requirements and Commitments.}
EMA, GVP Module XVI: Risk minimisation measures.^{2European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module XVI – Risk minimisation measures.}

The decision practice behind the memo itself is on the template page.

What gets flagged

Any interim result reported as final, any measure judged effective without data, and any requirement whose terms were not supplied.

What arrives

Decision and therapeutic context
Benefit-risk conclusion
Effects table
What each seat concludes
Weighing matrix by seat and criterion
Uncertainties and sensitivity
Risk minimisation and monitoring
What would change the balance

What it will not do

It does not replace a regulator or a benefit-risk committee. The conclusion is analyst judgment from AI specialists, and the decision stays with you.

It does not decide whether the requirement is fulfilled.

It does not replace a regulator or a benefit-risk committee. The conclusion is analyst judgment from AI specialists.

It does not compute a single benefit-risk score or invent patient preferences.

It does not add an effect that no source supports. Missing data are marked as gaps.

References

[1] U.S. Food and Drug Administration. Postmarketing Requirements and Commitments. Known from FDA’s site; not read in full.
[2] European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module XVI – Risk minimisation measures. Not read in full.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.

About the Panel service

Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.

To edit a saved template, open New → Panel → From template, or the library rail on the service form.